, locoregional or distant recurrence or contralateral breast cancer), postmenopausal women with hormone receptor–positive breast cancer should consider an AI, either as primary adjuvant therapy for 5 years or sequentially after 2 to 3 years of tamoxifen to yield a total of 5 years of adjuvant endocrine
therapy. Women who discontinue initial AI
therapy before 5 years should consider using tamoxifen to bring the total duration of adjuvant therapy to 5 years.